Cargando...
The progress and challenge of anti-PD-1/PD-L1 immunotherapy in treating non-small cell lung cancer
The use of programmed cell-death protein 1 (PD-1)/programmed cell-death ligand 1 (PD-L1) inhibitors is the standard therapy for the first-line or second-line treatment of patients with non-small-cell lung cancer (NSCLC). In contrast to current traditional treatments such as chemotherapy or radiother...
Guardado en:
| Publicado en: | Ther Adv Med Oncol |
|---|---|
| Autores principales: | , , , , , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
SAGE Publications
2021
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7890731/ https://ncbi.nlm.nih.gov/pubmed/33643442 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835921992968 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|